Merck Welireg Fails, Roche Enspryng Shines in Trials | Pharma and Biotech Daily

About this episode

The episode discusses the setbacks and successes of Merck's Welireg and Roche's Enspryng in recent clinical trials.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore some of the pivotal shifts and breakthroughs shaping the industry and their implications for drug development and patient care. In oncology, Merck & Co.'s Welireg triplet therapy faced a setback in its Phase 3 trial for first-line treatment of kidney cancer. Despite previous successes, this outcome underscores the complexity of developing ...

People in this episode

Host: Pharma and BioTech News

Topics covered

• oncology
• drug development
• clinical trials
• biotech news
• patient care

Keywords

• Merck
• Welireg
• Roche
• Enspryng
• clinical trials
• oncology
• biotech

Mentioned in this episode

Organizations: Merck & Co., Roche

Products: Welireg, Enspryng

Places: kidney cancer

More episodes of Pharma and BioTech Daily

• Takeda's Zasocitinib Beats Sotyktu in Phase 3 Trial | Pharma and Biotech Daily · June 12, 2026 · 5 min
• Pfizer CEO Rethinks Germany Investments Amid Reform Concerns | Pharma and Biotech Daily · June 11, 2026 · 5 min
• Merck & Gilead's HIV Pill Breakthrough: Phase 3 Success! | Pharma and Biotech Daily · June 10, 2026 · 5 min
• Eli Lilly's Retatrutide Breakthrough: 30.3% Weight Loss Success | Pharma and Biotech Daily · June 9, 2026 · 5 min
• Pfizer & Chai AI Breakthrough: $1.675B Gilead Deal | Pharma and Biotech Daily · June 8, 2026 · 5 min
• Eli Lilly & Boehringer Cut $1B+ Investments in Germany | Pharma and Biotech Daily · June 5, 2026 · 5 min